Skip Navigation


European Heart Journal Advance Access originally published online on July 4, 2006
European Heart Journal 2006 27(15):1773-1777; doi:10.1093/eurheartj/ehl123
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/15/1773    most recent
ehl123v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by McMurray, J.
Right arrow Articles by Swedberg, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMurray, J.
Right arrow Articles by Swedberg, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Treatment of chronic heart failure: a comparison between the major guidelines

John McMurray1,* and Karl Swedberg2,3

1 Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
2 Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden
3 Department of Medicine, Sahlgrenska University Hospital/Östra, 416 45 Göteborg, Sweden

Received 6 June 2006; accepted 8 June 2006; online publish-ahead-of-print 4 July 2006.

* Corresponding author. Tel: +44 141 211 1838; fax: +44 141 211 2252. E-mail address: j.mcmurray{at}bio.gla.ac.uk

Abstract

Because of rapid advances in the treatment of chronic heart failure, four important guidelines, including those from the European Society of Cardiology, have recently been updated. This review compares and contrasts the levels of evidence and classes of recommendation given to each of the key pharmacological and device therapies advocated by these guidelines. Possible explanations for discrepancies between the guidelines are discussed. Future approaches that might clarify the grade of evidence allocated and class of recommendation made are also described.

Key Words: Heart failure • Guidelines • ACE inhibitor • Beta-blocker • Angiotensin receptor blocker • Aldosterone antagonist


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
K. Swedberg
Pure heart rate reduction: further perspectives in heart failure
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F20 - F24.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
I. Ekman and K. Swedberg
Patients' Persistence of Evidence-Based Treatment of Chronic Heart Failure: A Treatment Paradox
Circulation, August 14, 2007; 116(7): 693 - 695.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
G. Filippatos and D. T. Kremastinos
Beta-blockers in asymptomatic dilated cardiomyopathy: to b-block or not to b-block?
Eur. Heart J., May 1, 2007; 28(9): 1170 - 1171.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.